[Neoplasm prevalence in renal transplantation].
| Autor: | Gómez dos Santos V; Servicio de Urología y Nefrología, Hospital Ramón y Cajal, Departamento de Ciencias Morfológicas y Cirugía, Universidad de Alcalá, Madrid, España., Burgos Revilla FJ, Pascual Santos J, Orofino Ascunce L, Fernández-Juárez G, Crespo Martínez L, Clemente Ramos L, Carrera Puerta C, Marcen Letosa R, Escudero Barrilero A, Ortuño Mirete J |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Archivos espanoles de urologia [Arch Esp Urol] 1997 Apr; Vol. 50 (3), pp. 267-73; discussion 273-4. |
| Abstrakt: | Objective: To analyze the prevalence of neoplasms in renal transplant patients and the relative risk for each tumor type according to the immunosuppression regimen. Methods: 609 renal transplants were reviewed. The risk index was determined by the ratio of the cases observed and predicted. Results: Tumor prevalence was 4.9% (30/609); 6.3% (25/393) were males and 2.3% (5/216) were females. The most common tumors were cutaneous tumors other than melanoma, accounting for 2.4% (15/609), followed by Kaposi's sarcoma, pulmonary epidermoid carcinoma and genitourinary tumors (0.5%) and non-Hodgkin lymphoma (0.3%). Tumor prevalence was 6.8% for the group treated with azathioprine-prednisone and 3.9% for the cyclosporine A-prednisone-treated group. The estimated relative risk of having a neoplasm was 10-fold higher for the males and 4.2-fold higher for the females vs the general population. The mortality rate was 36.6%; specifically tumor-related in 82%. The mortality rate for those with solid tumors was 77.7%. The long-term survival rate for the group that developed a tumor was significantly lower than that of the general population, 75% vs 53%, respectively (p < 0.05). Conclusion: In this series no significant differences were observed relative to tumor prevalence or type according to the immunosuppression regimen. A recipient of a renal graft has a higher risk of developing a tumor. Cutaneous tumors were the most frequent. The long-term survival is lower for recipients of renal grafts who develop a tumor. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|